Compare · ARGX vs LXEO
ARGX vs LXEO
Side-by-side comparison of argenx SE (ARGX) and Lexeo Therapeutics Inc. (LXEO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARGX and LXEO operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- ARGX is the larger of the two at $50.79B, about 235.4x LXEO ($215.8M).
- Over the past year, ARGX is down 1.9% and LXEO is down 70.0% - ARGX leads by 68.1 points.
- LXEO has been more active in the news (12 items in the past 4 weeks vs 6 for ARGX).
- ARGX has more recent analyst coverage (25 ratings vs 11 for LXEO).
- Company
- argenx SE
- Lexeo Therapeutics Inc.
- Price
- $819.19-3.28%
- $2.63-4.18%
- Market cap
- $50.79B
- $215.8M
- 1M return
- -17.73%
- -37.11%
- 1Y return
- -1.87%
- -69.99%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- 2023
- News (4w)
- 6
- 12
- Recent ratings
- 25
- 11
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Latest ARGX
- argenx to Report Third Quarter 2026 Financial Results and Business Update on October 22, 2026
- SEC Form 6-K filed by argenx SE
- argenx Provides Update on Phase 3 UNITY Study of Efgartigimod SC in Sjögren's Disease
- argenx Announces Positive Topline Results from Phase 2 Study of FB102 in Celiac Disease
- SEC Form 6-K filed by argenx SE
- argenx Presents New Data at AANEM and MGFA Scientific Session Showcasing Earlier and Sustained Treatment in MG and CIDP with VYVGART and Progress Across its Neuromuscular Pipeline
- argenx announces results of Extraordinary General Meeting of Shareholders and appointment of Thomas M. Brakel and Khurem Farooq as Non-Executive Directors
- argenx to Present at Upcoming Investor Conferences
- SEC Form 6-K filed by argenx SE
- Amendment: SEC Form SC TO-T/A filed by argenx SE
Latest LXEO
- SEC Form SCHEDULE 13G filed by Lexeo Therapeutics Inc.
- Lexeo Therapeutics to Participate in the Chardan Healthcare Conference
- Lexeo Therapeutics Announces Oral Presentation of LX2006 at the International Congress of Parkinson’s Disease and Movement Disorders 2026 (MDS)
- Lexeo Therapeutics Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
- SEC Form 4 filed by Chief Financial Officer Tamayo Louis Edward
- Chief Operating Officer Otero Jose Manuel was granted 2,110 shares, increasing direct ownership by 2% to 138,288 units (SEC Form 4)
- Chief Medical Officer Bhalla Narinder Pal was granted 2,714 shares, increasing direct ownership by 3% to 84,908 units (SEC Form 4)
- Chief Executive Officer Townsend Richard Nolan was granted 2,306 shares, increasing direct ownership by 0.62% to 376,778 units (SEC Form 4)
- Apertura Gene Therapy to Provide Lexeo Therapeutics Access to TfR1 CapX™ for Program Designed to Treat Friedreich Ataxia
- Lexeo Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic Forum